Immuno-Oncology

Basic Information

English Title: Immuno-Oncology

ISSN (Print): 3105-6628

ISSN (Online): 3105-6636

CODEN: MZABB7

Identifier Assigning Organization: Chemical Abstracts Service (CAS), USA

Distribution Support: China International Book Trading Corporation (CIBTC)

Import Registration Number: G015Z129

Publication Model: Gold Open Access (Gold OA) under the CC BY 4.0 license, with permanent free full-text access

Publisher: Macau Sino-Foreign Medical Publishing Limited

Publication Frequency: Bimonthly

Languages of Publication: Chinese, English

Submission Requirements: Chinese submissions are accepted, with English title, abstract, keywords, author affiliations and names submitted simultaneously.

The journal has been indexed by many authoritative academic databases worldwide. It is committed to promoting the global dissemination of high-quality research and collaborating with scholars around the world to build an open, collaborative and forward-looking international academic community.

Core Positioning

Immuno-Oncology is an authoritative academic journal focusing on cutting-edge basic research and clinical translation innovation in tumor immunology. The journal is dedicated to systematically advancing theoretical breakthroughs and technological innovations in the field of tumor immunotherapy, with a focus on core scientific issues such as immune checkpoint regulatory mechanisms, dynamic remodeling of the tumor microenvironment, innovative cell therapy technologies, and the development of precise biomarkers. We particularly advocate an interdisciplinary integration research paradigm, integrating advanced methodological systems of immunology, tumor biology, molecular medicine, and computational biology, aiming to provide solid theoretical support and innovative solutions for the clinical practice of tumor immunotherapy.

Scope of Submissions

The journal focuses on the following cutting-edge research directions:

Molecular mechanisms and drug resistance evolution of immune checkpoint inhibitors

Innovation, optimization and clinical translation of next-generation cell therapy technologies such as CAR-T/NK/TCR-T

Analysis of the spatiotemporal dynamic regulatory network of the tumor immune microenvironment

Screening systems for tumor neoantigens and personalized immunotherapy strategies

Systematic discovery and clinical validation of biomarkers for immunotherapy response/resistance

Molecular mechanisms and precise management of immune-related adverse events

Design of novel tumor vaccines and innovation of combined therapy strategies

Interaction mechanisms between the microbiome and tumor immune response

Spatiotemporal synergetic effects of radiotherapy and immunotherapy

Design of immunotherapy clinical trials and construction of real-world evidence systems

Aims and Vision

The journal aims to build a globally influential academic hub for immuno-oncology, accelerating the translation of basic research findings into clinical treatment paradigms. We are committed to building an open and collaborative international academic network, providing a high-level dialogue platform for global researchers, clinical experts and industrial innovators, continuously promoting paradigm innovation in the field of tumor immunotherapy, and ultimately benefiting the cause of human health.